MedPath
Found 1 clinical trials|View Analysis
Sort by:

A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: SL-801
First Posted Date
2016-01-29
Last Posted Date
2024-05-24
Lead Sponsor
Stemline Therapeutics, Inc.
Target Recruit Count
72
Registration Number
NCT02667873
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Florida Cancer Specialist, Sarasota, Florida, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath